Form 4: Forte Biosciences Director Receives Stock Units

Forte Biosciences Director Scott C. Brun was granted 18,353 Restricted Stock Units (RSUs) vesting in May 2026.

Summary

• Scott C. Brun, a Director at Forte Biosciences, Inc., was granted 18,353 Restricted Stock Units (RSUs) on May 29, 2026.
• These RSUs represent a contingent right to receive one share of Forte Biosciences' Common Stock.
• The RSUs are subject to Mr. Brun's continued service as a Service Provider through the vesting date.
• Vesting is scheduled for the first annual stockholders' meeting occurring after May 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard director compensation event (RSU grant) without providing new financial performance data or strategic updates.

Positives

• Director compensation through equity awards can align management interests with shareholder value.
• The grant of RSUs indicates continued investment in key personnel and potential future performance.

Risks

• The vesting of RSUs is contingent on the reporting person's continued service, implying a risk of forfeiture if service is terminated before the vesting date.
• The value of the RSUs is tied to the future performance of Forte Biosciences' stock, which carries inherent market risks.

Future Outlook

The RSUs are set to vest on the date of the first annual stockholders' meeting after May 29, 2026, subject to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units (RSUs), are a common form of compensation for directors and executives in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation that may dilute existing share ownership over time, but it also aims to align director incentives with long-term shareholder value creation.
• Employees: The continued service requirement for vesting may indirectly impact employee morale and retention if key personnel are perceived to be leaving before vesting.
• Management: The RSU grant is a direct benefit to Director Scott C. Brun, contingent on his continued role.

Next Steps

• Vesting of 18,353 RSUs on the first annual stockholders' meeting after May 29, 2026, contingent on continued service.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Stock Vesting